ValuEngine upgraded shares of Immunomedics (NASDAQ:IMMU) from a sell rating to a hold rating in a report published on Friday morning.

Other equities analysts have also issued research reports about the company. Zacks Investment Research lowered Immunomedics from a buy rating to a hold rating in a research note on Wednesday, November 15th. Jefferies Group raised their price target on Immunomedics from $14.00 to $16.00 and gave the company a buy rating in a research note on Monday, October 9th. Finally, BidaskClub upgraded Immunomedics from a hold rating to a buy rating in a research note on Friday, December 22nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $19.00.

Immunomedics (NASDAQ IMMU) opened at $16.25 on Friday. The company has a market capitalization of $2,470.00, a price-to-earnings ratio of -7.25 and a beta of 1.50. The company has a debt-to-equity ratio of -0.29, a quick ratio of 0.74 and a current ratio of 0.74. Immunomedics has a 52 week low of $4.08 and a 52 week high of $18.93.

Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.06). The firm had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.90 million. analysts forecast that Immunomedics will post -1.16 EPS for the current year.

In other Immunomedics news, Director Brian A. Markison sold 8,390 shares of Immunomedics stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $11.89, for a total value of $99,757.10. Following the transaction, the director now owns 99,178 shares in the company, valued at $1,179,226.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Venbio Select Advisor Llc bought 1,150,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was bought at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The disclosure for this purchase can be found here. 6.60% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of IMMU. FMR LLC grew its stake in Immunomedics by 260.6% in the second quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock valued at $48,537,000 after purchasing an additional 3,972,388 shares during the last quarter. NEA Management Company LLC purchased a new position in Immunomedics in the third quarter valued at about $38,762,000. State Street Corp grew its stake in Immunomedics by 37.2% in the second quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock valued at $42,549,000 after purchasing an additional 1,305,298 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in Immunomedics in the second quarter valued at about $10,570,000. Finally, Victory Capital Management Inc. purchased a new position in Immunomedics in the fourth quarter valued at about $17,941,000. Institutional investors own 75.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/02/05/immunomedics-immu-stock-rating-upgraded-by-valuengine.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.